Bliss GVS Pharma share news, announcements and annual reports
NSE: BLISSGVSBSE: 506197Pharmaceuticals & BiotechnologySmall Cap
Bliss GVS Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1985 on BSE, Jul 2010 on NSE
Last close ₹647.50down ₹33.40 (4.91%)BSE ₹648.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹680.90.
30 Oct: open ₹660.00, high ₹670.00, low ₹646.90
52-week range of traded prices to 30 Oct 2026
₹118.00Low, 10 Nov 2025₹739.90High, 28 Sep 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,885 Cr1,000th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.71
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.23%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,45,760
Bliss GVS Pharma board meetings
110 filed, newest first. Page 1 of 3.
Oct 2026
1 Oct · Board meeting
Sep 2026
28 Sep · Board meeting
Aug 2026
Jul 2026
3 Jul · Board meeting
May 2026
23 May · Board meeting
Apr 2026
Feb 2026
Dec 2025
23 Dec · Board meeting
Nov 2025
6 Nov · Board meeting
Oct 2025
Sep 2025
30 Sep · Board meeting
Jul 2025
22 Jul · Board meeting
May 2025
Jan 2025
28 Jan · Board meeting
Oct 2024
24 Oct · Board meeting
Jul 2024
Apr 2024
Jan 2024
Nov 2023
1 Nov · Board meeting
Oct 2023
Aug 2023
1 Aug · Board meeting
Jul 2023
May 2023
5 May · Board meeting
Meeting on 11 May 2023: “BLISS GVS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 11-May-2023 to consider financial statements for the period ended March 2023, Financial results/Dividend/Other busi”
Jan 2023
18 Jan · Board meeting
Dec 2022
30 Dec · Board meeting
Nov 2022
Oct 2022
Aug 2022
Jul 2022
Apr 2022
Jan 2022
Oct 2021
30 Oct · Board meeting
22 Oct · Board meeting
Jul 2021
31 Jul · Board meeting
23 Jul · Board meeting
May 2021
3 May · Board meeting
Jan 2021
Oct 2020
13 Oct · Board meeting
Aug 2020
Jun 2020
16 Jun · Board meeting